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Abstract: Preterm birth is the leading cause of perinatal morbidity and mortality. Fetal 
fibronectin (fFN), a glycoprotein in the extracellular matrix of the amniotic membranes, is 
the most powerful biomarker for predicting the risk of preterm birth. Biosensors using the 
surface plasmon resonance (SPR) response are potentially useful in quantitatively measuring 
molecules. We established a standard calibration curve of SPR intensity against fFN 
concentration and used the SPR-based biosensor to detect fFN concentrations in the 
cervicovaginal secretions of pregnant women between 22 and 34 weeks of gestation. The 
calibration curve extends from 0.5 ng/mL to 100 ng/mL with an excellent correlation  
(R
2 = 0.985) based on standard fFN samples. A cutoff value of 50 ng/mL fFN concentration 
in commercial ELISA kits corresponds to a relative intensity of 17 arbitrary units (a.u.) in 
SPR. Thirty-two pregnant women were analyzed in our study. In 11 women, the SPR 
relative intensity was greater than or equal to 17 a.u., and in 21 women, the SPR relative 
intensity was less than 17 a.u. There were significant differences between the two groups in 
regular uterine contractions (p  = 0.040), hospitalization for tocolysis (p  = 0.049), and 
delivery weeks (p = 0.043). Our prospective study concluded that SPR-based biosensors can 
quantitatively measure fFN concentrations. These results reveal the potential utility of 
SPR-based biosensors in predicting the risk of preterm birth.  
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1. Introduction 
Preterm birth is defined by the World Health Organization as delivery at less than 37 gestational 
weeks [1]. It is the main cause of perinatal morbidity and mortality, with an incidence of 5 to 13% in 
developed countries, and it accounts for nearly 70% of neonatal deaths and 50% of neurological 
disabilities [2–5]. Early detection of preterm birth is difficult because the initial signs and symptoms are 
often obscure and may be mimicked by normal pregnancies. Therefore, it is essential to find biomarkers 
to predict the risk of preterm birth. Previous studies have revealed that various biomarkers in 
cervicovaginal secretions are related to preterm birth, such as fetal fibronectin (fFN), interleukin-6 
(IL-6), monocyte chemotactic protein-1 (MCP-1), phosphorylated insulin-like growth factor binding 
protein-1 (phIGFBP-1), and matrix metalloproteinase-8 (MMP-8) [6–10]. Of these biomarkers, the most 
powerful is fFN because of its high negative predictive value: only 1% of pregnant women with a 
negative fFN result deliver within the next week [2,11–13].   
fFN is a glycoprotein found in the extracellular matrix of the amniotic membranes [14]. It can be 
distinguished from other human fibronectin proteins because of the specific III-CS (connecting segment) 
epitope, which is recognized by the FDC-6 monoclonal antibody in immunohistochemical staining [15,16]. 
fFN is generally found in cervicovaginal secretions until 22 gestational weeks; it then diminishes between 
22 and 34 gestational weeks and increases again near term in normal pregnancies. However, preterm 
labor induces the release of fFN into the ectocervix or posterior vaginal fornix. The putative mechanisms 
of fFN release are either the mechanical force caused by uterine contractions leading to choriodecidual 
separation or inflammation resulting from subclinical bacterial infection that degrades the choriodecidual 
interface [17,18]. Numerous studies have demonstrated the clinical usefulness of fFN in predicting the risk 
of preterm labor [12,13,19–21]. The FDA has approved an fFN enzyme-linked immunosorbent assay 
(ELISA) and a lateral flow, solid-phase immunochromatographic assay (Rapid fFN Cassette) (TLi system, 
Adeza Biomedical Corporation, Sunnyvale, CA, USA) to predict the risk of preterm birth. In these 
assays, an fFN concentration greater than or equal to 50 ng/mL is defined as a positive result and shows 
a higher risk of preterm birth. However, these two conventional methods have some drawbacks. The 
ELISA method is time consuming, and its results are influenced by the color signal intensity, whereas 
the Rapid fFN Cassette is not a quantitative method. Therefore, a quantitative, label-free, and 
easy-to-perform assay is required. 
In recent years, a biosensor using the response of surface plasmon resonance (SPR) was 
introduced [22–24]. SPR is an electromagnetic reaction of surface plasmons at the metal–dielectric 
interface of biosensors. In theory, when the analyte binds the ligand on the metal film, the interfacial 
architecture changes, and surface plasmons are excited by the light beam. We can measure the change of 
the resonant angle and determine the concentration of biomolecules of interest. SPR intensity 
measurement effectively enhances the accuracy of many spectroscopic measurements because it not 
only has a highly sensitive response in biomolecular interactions, but it also allows real-time monitoring 
in label-free environments. We performed a prospective study to detect fFN concentrations in the Sensors 2012, 12  
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cervicovaginal secretions of pregnant women between 22 and 34 gestational weeks using SPR-based 
biosensors and attempted to predict the risk of preterm birth using these fFN measurements.   
2. Materials and Methods  
2.1. Sample Collection 
We performed the study in the delivery room of the Mackay Memorial Hospital from October 2009 to 
May 2010. The cervicovaginal secretions of pregnant women who complained of low abdominal pain  
or uterine contractions between 22 and 34 gestational weeks were collected by speculum examination 
before performing any other transvaginal procedures such as vaginal ultrasound and endocervical culture, 
which may rub the cervical mucosa and thus interfere with sample collection. We slightly inserted the tip 
of a sterile cotton swab to the posterior fornix of the vagina and rotated the swab for 10 s to absorb 
secretions. After removing the cotton swab, we inserted the tip of the cotton swab into a tube containing 
3 mL of phosphate buffered saline (PBS) and mixed vigorously for 10 s [25]. We then sent the fFN 
samples to the laboratory for SPR detection. The study was approved by the Mackay Memorial Hospital 
Institutional Review Board (IRB #09MMHIS056). 
2.2. Fabrication of SPR Chip Substrates 
Two different sensing substrates, Au (50 nm) and Cr (2 nm), were used as the electroplating 
materials. Standard glass microscope slides (SF-10, Schott Glass) were used as base substrates. The 
slides were first cleaned with piranha solution (H2SO4:H2O2 = 3:1) for 10 min and then rinsed three 
times with deionized water. The slides were then dried with nitrogen gas. Au and Cr films were 
deposited on the slides by an electron beam evaporator at a vacuum level of about 3 × 10
−6 Torr.   
2.3. Preparation of the Biosensor Surface 
First, the gold-coated slide was immersed into an 8-mercaptooctanoic acid (8-MOA) solution  
with a concentration of 10 mM at room temperature (approximately 25 °C) for 30 min [22]. Then,  
the chemically immobilized surface was activated using 400 mM 1-ethyl-3-(3-dimethylaminopropyl)- 
carbodiimide (EDC)/100 mM N-hydroxysuccinimide (NHS) for covalent bond formation in 15 min at 
room temperature. Next, the gold film chip was soaked in 50 µg/mL protein G solution, which was fixed 
on the gold surface for 15 min. Then, 0.5 µg/mL rabbit monoclonal fFN antibody (Abcam, ab32419), 
reacting with a recombinant full length protein, was fixed onto the surface for 30 min. Finally, the surface 
of the chip was blocked with 1% bovine serum albumin (BSA) for 10 min. All steps were performed at 
room temperature. 
2.4. SPR Measurement 
SPR signal detection  was accomplished using a GWC SPR Imager (GWC Technologies Inc. 
Madison, WI, USA). All measurements were performed at a fixed incident angle close to the SPR angle. 
First, PBS was allowed to flow over the sensing surface until a stable baseline was obtained. This step 
was followed by the introduction of the fFN solution onto the antibody-immobilized surface at a rate of  Sensors 2012, 12  
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40 µL/min for 10 min. Next, unbound fFN antigens were washed out with PBS for another 10 min to 
achieve equilibrium. The measured value of the SPR reflectivity is expressed in arbitrary units (a.u.).  
2.5. Data Analysis 
Statistical analysis was performed with Student’s t test for continuous variables and the Χ
2 test for 
categorical data. For continuous variables, the results are presented as the mean ± standard deviation.  
p < 0.05 was considered statistically significant. A calibration curve was established using Sigma  
Plot software version 10.0 and fitted with the four-parameter logistic equation, which can be expressed 
as [26]:  
Y ＝ I L ＋ (IH − IL)/[1 ＋ (C/C1/2)
s] 
in which Y represents the SPR intensity signal, IL is the minimal SPR relative intensity, IH is the 
maximal SPR relative intensity, C is the analyte concentration, C1/2 is the inflexion point concentration 
corresponding to the half-maximal SPR relative intensity, and S is the slope at the inflection point of the 
calibration curve. 
A receiver-operating characteristic (ROC) curve was constructed to seek the optimum cut-off point of 
delivery week prediction for the group with higher SPR relative intensity. The optimum cut-off point 
was defined as the closest point on the ROC curve to the point (0, 1), that is, a false positive rate of zero 
and a sensitivity of 100%. The area under the curve (AUC) and 95% confidence interval (CI) were 
calculated. Statistical analysis was performed using the Statistical Package for the Social Sciences 
(SPSS), version 18.0. 
Figure 1. Calibration curve of SPR intensity against the concentrations of fetal fibronectin 
(fFN) (0.5, 1, 5, 10, 50, and 100 ng/mL), with a correlation coefficient (R
2) of 0.985. The SPR 
intensity corresponding to the fFN ELISA critical concentration of 50 ng/mL was 17 a.u. 
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3. Results and Discussion 
3.1. Calibration Curve Establishment 
A calibration curve of SPR responses was first established from triplicate measurement of fFN 
antigen concentrations ranging between 0.5 ng/mL and 100 ng/mL, as shown in Figure 1. SPR relative 
intensities were measured with concentrations of 0.5, 1, 5, 10, 50, and 100 ng/mL of fFN antigen over  
a chip fixed with 0.5 µg/mL fFN antibody. The investigational data revealed excellent agreement when 
ﬁtted to the calibration curve, with a correlation coefficient (R
2) of 0.985. The SPR intensity corresponding 
to the critical concentration of 50 ng/mL in the fFN ELISA assay for the risk evaluation of preterm birth 
was 17 a.u,. The SPR intensity response increased with increasing fFN concentration, within certain limits.  
3.2. SPR Sensorgram of the Sample 
One example (no. 23 in Table 1) of an SPR sensorgram of a sample from a pregnant woman at  
33 gestational weeks is shown in Figure 2. About 1,100 s elapsed from the beginning of antibody-antigen 
association to the end of antibody-antigen dissociation. Therefore, we evaluated the fFN concentration in 
clinical samples according to the average dynamic fitting curve. The average SPR relative intensity was 
11.19 a.u. In this case, the uterine contraction duration/interval was 20 s/5 min, and the cervical os was 
not dilated by speculum examination. Hospitalization for tocolytic therapy was not suggested by the 
evaluation of obstetricians, and the woman did not deliver until 41 gestational weeks. The clinical result 
was compatible with the lower level of fFN measurement (<17 a.u.).  
Table 1. Patient characteristics. 
Patient 
No. 
Detection 
weeks 
SPR relative 
intensity 
(a.u.)  
Cervical 
dilatation  
(cm) 
Uterine 
contractions 
(duration/interval)
Hospitalization 
for tocolysis 
Delivery 
weeks 
1  30  0.93  0  20′′/3–5′  No  40 
2  34  9.85  0  5′′/2–3′  Yes  38 
3  23  8.86  0  20′′/5–6′  No  39 
4  25  8.58  0  15′′/4′  Yes  38 
5  23  5.93  0  irregular  Yes  35 
6  26  29.97  0  20–30′′/2–3′  Yes  27 
7  32  4.33  0  irregular  Yes  37 
8  25  23.34  0  15′′/5–8′  Yes  34 
9  30  20.63  2  20′′/3′  Yes  38 
10  33  3.49  0  20′′/5–6′  Yes  36 
11  32  32.72  0  10′′/2–3′  Yes  37 
12  34  5.76  0  irregular  No  38 
13  33  7.33  1  20′′/3–6′  Yes  33 
14  32  10.42  2  10′′/2–3′   Yes  32 
15  32  25.31  0  10′′/6–7′  Yes  36 
16  33  15.99  0  10′′/2–3′   No  37 
17  25  47.95  0  1′/6–7′   Yes  26 
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Table 1. Cont. 
Patient 
No. 
Detection 
weeks 
SPR relative 
intensity 
(a.u.)  
Cervical 
dilatation  
(cm) 
Uterine 
contractions 
(duration/interval)
Hospitalization 
for tocolysis 
Delivery 
weeks 
18  31  13.01  0  20′′/8′  Yes  37 
19  33  15.39  0  15′′/3–6′   Yes  34 
20  26  31.44  1  15′′/5–8′  Yes  35 
21  34  15  0  15′/3–6′   No  38 
22  33  10.68  0  20′′/2–3′  Yes  37 
23  33  11.19  0  20′′/5′  No  41 
24  28  13.15  0  10′′/6–7′  Yes  30 
25  33  8.46  0  10′′/2–5′  Yes  35 
26  34  13.51  0  20′′/5′  Yes  40 
27  22  26.01  0  10′′/3′  Yes  22 
28  22  10.63  0  irregular  Yes  40 
29  33  17.99  0  20′′/5–6′  Yes  36 
30  33  42.19  0  10′′/3′  Yes  35 
31  27  7.08  0  5–10′′/2–3′  Yes  40 
32  33  18.02  1  10–15′′/2–3′  Yes  37 
Figure 2. Sensorgram of a clinical sample from a pregnant woman at 33 gestational weeks. 
(a) Association, (b) Steady state, and (c) Dissociation of the antibody-antigen. 
 
3.3. Analysis of Clinical Samples 
Sixty-four samples were obtained. After excluding the cases of advanced cervical dilation (≥3 cm), 
rupture of amniotic membranes, significant vaginal bleeding, sexual intercourse within 24 h, multiple 
gestations, and prior tocolytic therapy in this pregnancy, 32 clinical samples were analyzed (Table 1). 
Preterm delivery usually ensues after advanced cervical dilation or rupture of amniotic membranes; fFN 
measurement is therefore not useful for these cases. Remarkable vaginal bleeding may be related to 
other obstetric problems such as placenta previa or abruptio placenta, which are the other important risk Sensors 2012, 12  
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factors of preterm birth. In addition, testing a sample with amniotic fluid, blood, or semen may increase 
the possibility of false positive results. 
The average detection weeks were 29.91 ± 4.08 (range 22 to 34 weeks), and delivery weeks were 
35.56 ± 4.28 (range 22 to 41 weeks). No cervical dilation was found in 27 (84.38%) cases. Twenty-six 
(81.25%) of the pregnant women were admitted to the hospital for tocolytic therapy after the evaluation 
of obstetricians. Eleven (34.38%) of the 32 samples had an SPR intensity greater than or equal to 17 a.u., 
and 21 (65.62%) had an SPR intensity less than 17 a.u. No statistically significant differences were found 
between the two groups in detection weeks and cervical dilation. These results may have occurred because 
we excluded cases of advanced cervical dilatation from analysis. However, there were significant 
differences between the two groups in regular uterine contractions (duration ≥ 10 s and interval ≤ 3 min)  
(p = 0.040), hospitalization for tocolysis (p = 0.049), and delivery weeks (p = 0.043) (Table 2). These 
findings agree with previous studies performed using the fFN ELISA test [12,13,19–21]. In our study, 
regular uterine contractions were noted in six (54.55%) of the 11 pregnant women with SPR intensity 
greater than or equal to 17 a.u., but only in four (19.05%) of the 21 pregnant women with SPR intensity 
less than 17 a.u. (p  = 0.040). Uterine contractions may cause placental shearing, which induces 
separation of the chorion layer from the decidual layer of the uterus, and then fFN is released into the 
cervix and vagina. Hospitalization for tocolysis occurred in all (100%) of the 11 pregnant women with 
higher SPR intensity, but only 15 (71.43%) of the 21 pregnant women with lower SPR intensity  
(p = 0.049) were hospitalized for tocolysis. Clinically, after excluding medical or surgical problems 
(such as acute gastroenteritis or appendicitis) and other potential obstetric causes of preterm labor (such 
as abruptio placenta), obstetricians evaluate the severity of uterine contractions and/or the progression of 
cervical dilation to decide the necessity of hospitalization for tocolysis. Finally, we found that delivery 
occurred nearly four weeks earlier in the group with higher SPR intensity (33.00 ± 5.39 vs. 36.90 ± 2.90,  
p = 0.043). These results show that preterm delivery prediction by fFN detection can be accomplished 
using our chip, and the SPR-based biosensor is another choice for fFN measurement.  
Table 2. Demographic data between SPR relative intensity ≥17 a.u. and <17 a.u. 
SPR relative intensity  ≥17 a.u.  <17 a.u.  p value
No.  11 (34.38%)  21 (65.62%)   
Detection weeks  28.82 ± 4.07  30.48 ± 4.07  0.282 
Cervical dilatation (cm)  0.36  0.14  0.290 
Regular uterine contractions (≥10′′/≤3′)  6 (54.55%)  4 (19.05%)  0.040 
Hospitalization for tocolysis  11 (100%)  15 (71.43%)  0.049 
Delivery weeks  33.00 ± 5.39  36.90 ± 2.90  0.043 
3.4. ROC Curve of Higher SPR Intensity 
Figure 3 shows an ROC curve and the optimum cut-off point of predicting delivery weeks in the 
group with SPR relative intensity greater than or equal to 17 a.u. The AUC was 0.751 for delivery weeks 
(p = 0.021, 95% CI 0.582–0.920). On constructing the ROC curve, we revealed that a cut-off value of  
37 gestational weeks in the group with higher SPR intensity provided the best sensitivity (66.7%) and 
specificity (72.7%) for predicting risk of preterm birth. These results agree with the definition of preterm 
birth as delivery at less than 37 gestational weeks [1].   Sensors 2012, 12  
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Figure 3. Receiver-operating characteristic (ROC) curve for predicting the delivery   
weeks for the group with higher SPR relative intensity. The optimum cut-off point (open 
circle) was defined as the closest point on the ROC curve to the point (x, y) = (0, 1), where  
x = 1 − specificity and y = sensitivity.  
 
3.5. SPR-Based Biosensors versus ELISA   
Many methods have been used to detect the concentration of biomarkers. The most prevalent method  
for the quantitative detection of molecules in biological samples is ELISA. The principle of ELISA is based 
on two main procedures: (1) utilizing a primary antibody to bind the antigen of interest; (2) labeling a 
secondary enzyme-linked antibody to produce a quantitative alteration for measurement [27]. ELISA 
has many advantages, such as widely available facilities, reagents with long shelf lives, and a lack of 
radioactive dangers during labeling or waste disposal (compared with radioimmunoassay). However, 
ELISA also has some disadvantages, such as its time-consuming nature (more labeling and detection 
steps), its more expensive kits, the effects of biological matrices on enzyme activity, and the decay of 
color signal intensity. Further technologies have been developed to overcome these drawbacks; 
examples include mass spectrometry, flow cytometry, SPR, and recent immunomagnetic reduction [28].  
In contrast to ELISA, the SPR-based biosensor is real-time, label-free, fast, and low-cost. It can 
quantitatively measure molecules of interest without the need for secondary antibodies to generate signals. 
Furthermore, in real-time analysis, SPR-based biosensors can illustrate association and dissociation  
phases and determine the affinity and kinetics of molecular interaction [29–31]. Many studies have  
also demonstrated that the SPR-based biosensor is more sensitive than ELISA and has a similar 
specificity [32–36]. In Taiwan, the commercial fFN ELISA kit is not widely used because of its higher 
cost. However, the AUC, sensitivity, and specificity of our data were similar to that of previous studies 
with ELISA [21,37]. In the cases that did not fall in the ROC curve, we additionally assessed the cervical 
length under ultrasound to predict the risk of preterm labor [38]. According to the instructions of the fFN 
ELISA kit, the test results are generally available within 24 to 48 h after sample collection. Our 
SPR-based biosensor allows fast measurement in about 2 h. This time advantage is crucial for making Sensors 2012, 12  
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decisions in urgent situations. Furthermore, SPR-based biosensor platforms to perform simultaneous 
multi-target measurement have become available in recent years [39,40]. Thus it is possible to detect  
the above-mentioned biomarkers of preterm labor simultaneously, such as IL-6, MCP-1, phIGFBP-1, 
and MMP-8 [6–10], improving the accuracy of predicting the risk of preterm delivery. The SPR-based 
biosensor is a tool with great potential, and recent studies have focused on the development of high 
throughput and microinstrumentation of biosensors [41–44], further increasing its potential.  
4. Conclusions 
In this study, we constructed a fitting curve of standard fFN concentrations and compared standards 
with clinical samples. Our results show that SPR-based biosensors can quantitatively analyze fFN 
concentrations. The SPR-based biosensor is a promising method with quantitative detection, high 
sensitivity, high specificity, easy operation, and low cost. Our findings revealed the potential of the 
SPR-based biosensor in predicting the risk of preterm birth; the SPR-based biosensor may be a good 
alternative to conventional methods such as ELISA. Using SPR-based biosensors, we can diagnose 
preterm labor more accurately. A positive fFN test result can alert us to treat patients as soon as 
possible, such as by administering tocolytic therapy or steroids for fetal lung maturity and by referring 
patients to the tertiary medical center for better neonatal care, in order to decrease the incidence of 
perinatal morbidity and mortality. A negative fFN test result may reduce the over-diagnosis of preterm 
labor and avoid unnecessary medical intervention. 
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